Joshua A. Vieth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joshua A. Vieth has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Randall G. Worth
Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA
4 shared publications Adam J. Antczak
2 shared publicationsAlan D. Schreiber
Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
2 shared publicationsDavide Comoletti
2 shared publicationsDerek B Sant'ANgelo
2 shared publications- Derek B. Sant’angelo
Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
2 shared publications
Latest Publications
- 20 October 2026
- Published by American Diabetes Association in Diabetes
Clinical Trial Design Considerations for the Development of Disease-Modifying Therapies for Type 1 Diabetes
Type 1 diabetes remains a compelling target for disease-modifying therapy (DMT) development. The autoimmune pathophysiology is well characterized, a staging framework is established, and regulatory precedent now exists following the approval of teplizumab. While β-cell preservation has been demonstrated for several DMTs in phase 2 trials, few have advanced to registrational studies. This article is intended to reduce that gap through discussion of key considerations to guide drug developers and sponsors in the translation of type 1 diabetes DMTs. In outlining strategies to optimize overall regulatory strategy, clinical trial design, and end point selection, this framework positions DMT development for type 1 diabetes as not only scientifically feasible but also strategically tractable. Together, these considerations offer a road map to accelerate development and approval, with the goal of decreasing the time to benefit for those living with type 1 diabetes. Article Highlights: Several disease-modifying therapies have reduced the progressive loss of β-cell function in type 1 diabetes, with efficacy observed across a wide array of underlying therapeutic mechanisms of action. These successes highlight opportunities to accelerate the development of novel and repurposed type 1 diabetes treatments; however, only one such therapy has received regulatory approval for clinical use and few phase 3 clinical trials have been performed. For bringing emerging therapies to people living with type 1 diabetes as quickly and efficiently as possible, overall regulatory strategy and clinical trial design, especially inclusion criteria and end point selection, are essential, and planning must include their careful consideration. The considerations discussed herein represent a feasible and promising road map for developers of disease-modifying therapies and establish that type 1 diabetes remains a promising area for continued investment.
- 20 October 2026
- Published by American Diabetes Association in Diabetes
Clinical Trial Design Considerations for the Development of Disease-Modifying Therapies for Type 1 Diabetes
Type 1 diabetes remains a compelling target for disease-modifying therapy (DMT) development. The autoimmune pathophysiology is well characterized, a staging framework is established, and regulatory precedent now exists following the approval of teplizumab. While β-cell preservation has been demonstrated for several DMTs in phase 2 trials, few have advanced to registrational studies. This article is intended to reduce that gap through discussion of key considerations to guide drug developers and sponsors in the translation of type 1 diabetes DMTs. In outlining strategies to optimize overall regulatory strategy, clinical trial design, and end point selection, this framework positions DMT development for type 1 diabetes as not only scientifically feasible but also strategically tractable. Together, these considerations offer a road map to accelerate development and approval, with the goal of decreasing the time to benefit for those living with type 1 diabetes. Article Highlights: Several disease-modifying therapies have reduced the progressive loss of β-cell function in type 1 diabetes, with efficacy observed across a wide array of underlying therapeutic mechanisms of action. These successes highlight opportunities to accelerate the development of novel and repurposed type 1 diabetes treatments; however, only one such therapy has received regulatory approval for clinical use and few phase 3 clinical trials have been performed. For bringing emerging therapies to people living with type 1 diabetes as quickly and efficiently as possible, overall regulatory strategy and clinical trial design, especially inclusion criteria and end point selection, are essential, and planning must include their careful consideration. The considerations discussed herein represent a feasible and promising road map for developers of disease-modifying therapies and establish that type 1 diabetes remains a promising area for continued investment.
- Open Access
- 16 August 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2 (9) , 994
Publisher Correction: Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response
- 16 August 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2 (9) , 994
Open AccessPublisher Correction: Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response
- Open Access
- 31 July 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 203 (5) , 1230-1241
The Transcription Factor PLZF Is Necessary for the Development and Function of Mouse Basophils
Basophils are innate immune cells associated with type 2 immunity, allergic reactions, and host defense against parasite infections. In this study, we show that the transcription factor PLZF, which is known for its essential role in the function and development of several innate lymphocyte subsets, is also important for the myeloid-derived basophil lineage. PLZF-deficient mice had decreased numbers of basophil progenitors in the bone marrow and mature basophils in multiple peripheral tissues. Functionally, PLZF-deficient basophils were less responsive to IgE activation and produced reduced amounts of IL-4. The altered function of basophils resulted in a blunted Th2 T cell response to a protein allergen. Additionally, PLZF-deficient basophils had reduced expression of the IL-18 receptor, which impacted migration to lungs. PLZF, therefore, is a major player in controlling type 2 immune responses mediated not only by innate lymphocytes but also by myeloid-derived cells.
- 31 July 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 203 (5) , 1230-1241
Open AccessThe Transcription Factor PLZF Is Necessary for the Development and Function of Mouse Basophils
Basophils are innate immune cells associated with type 2 immunity, allergic reactions, and host defense against parasite infections. In this study, we show that the transcription factor PLZF, which is known for its essential role in the function and development of several innate lymphocyte subsets, is also important for the myeloid-derived basophil lineage. PLZF-deficient mice had decreased numbers of basophil progenitors in the bone marrow and mature basophils in multiple peripheral tissues. Functionally, PLZF-deficient basophils were less responsive to IgE activation and produced reduced amounts of IL-4. The altered function of basophils resulted in a blunted Th2 T cell response to a protein allergen. Additionally, PLZF-deficient basophils had reduced expression of the IL-18 receptor, which impacted migration to lungs. PLZF, therefore, is a major player in controlling type 2 immune responses mediated not only by innate lymphocytes but also by myeloid-derived cells.
- 1 August 2017
- Published by Springer Nature in Nature Immunology
- Vol. 18 (8) , 951
Erratum: Corrigendum: TCRα-TCRβ pairing controls recognition of CD1d and directs the development of adipose NKT cells
- 1 August 2017
- Published by Springer Nature in Nature Immunology
- Vol. 18 (8) , 951
Erratum: Corrigendum: TCRα-TCRβ pairing controls recognition of CD1d and directs the development of adipose NKT cells
- 3 July 2017
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 14 (8) , 658-661
Are fat NKT cells born that way?
- 3 July 2017
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 14 (8) , 658-661
Are fat NKT cells born that way?
- 21 November 2016
- Published by Springer Nature in Nature Immunology
- Vol. 18 (1) , 36-44
TCRα-TCRβ pairing controls recognition of CD1d and directs the development of adipose NKT cells
Sant/'Angelo and colleagues show that disruption of a hydrophobic patch in the T cell antigen receptor on natural killer T cells alters their development, which results in the selective accumulation of adipose-tissue-specific natural killer T cells.
- 21 November 2016
- Published by Springer Nature in Nature Immunology
- Vol. 18 (1) , 36-44
TCRα-TCRβ pairing controls recognition of CD1d and directs the development of adipose NKT cells
Sant/'Angelo and colleagues show that disruption of a hydrophobic patch in the T cell antigen receptor on natural killer T cells alters their development, which results in the selective accumulation of adipose-tissue-specific natural killer T cells.
- 1 January 2013
- Published by Elsevier in The American Journal of Pathology
- Vol. 182 (1) , 244-254
FcγRIIa Ligation Induces Platelet Hypersensitivity to Thrombotic Stimuli
- 1 January 2013
- Published by Elsevier in The American Journal of Pathology
- Vol. 182 (1) , 244-254
FcγRIIa Ligation Induces Platelet Hypersensitivity to Thrombotic Stimuli
- 4 September 2012
- Published by Springer Nature in Inflammation Research
- Vol. 62 (1) , 37-43
FcγRIIa requires lipid rafts, but not co-localization into rafts, for effector function
Objective To determine if receptor localization into lipid rafts, or the lipid rafts themselves, are important for FcγRIIa effector functions. Material Wild-type FcγRIIa or mutant FcγRIIa(C208A) that does not translocate to lipid rafts were transfected into Chinese hamster ovary (CHO) cells which have been shown to be reliable cells for studying FcγR function. Treatment Cells were treated with buffer or methyl-β-cyclodextrin (MβCD) to deplete cholesterol and dissolve the structure of lipid rafts. Methods To evaluate lipid raft association, transfected CHO cells were lysed and centrifuged over a sucrose gradient. Fractions were run on SDS-PAGE and blotted for FcγRIIa or sphingolipid GM1 to illustrate the lipid raft fractions. Lateral mobility of GFP-tagged wild-type or mutant FcγRIIa was assessed using fluorescence recovery after photobleaching (FRAP) microscopy. Internalization of IgG-opsonized erythrocytes was assessed by fluorescence microscopy and uptake of heat-aggregated IgG (haIgG) was measured using flow cytometry. Results We observed that FcγRIIa(C208A) did not localize into lipid rafts. However, the mutant FcγRIIa retained lateral mobility and effector function similar to wild-type FcγRIIa. However, mutant FcγRIIa function was abolished upon treatment with MβCD. Conclusions Lipid rafts provide an essential component required for effector activities independent of receptor localization.
- 4 September 2012
- Published by Springer Nature in Inflammation Research
- Vol. 62 (1) , 37-43
FcγRIIa requires lipid rafts, but not co-localization into rafts, for effector function
Objective To determine if receptor localization into lipid rafts, or the lipid rafts themselves, are important for FcγRIIa effector functions. Material Wild-type FcγRIIa or mutant FcγRIIa(C208A) that does not translocate to lipid rafts were transfected into Chinese hamster ovary (CHO) cells which have been shown to be reliable cells for studying FcγR function. Treatment Cells were treated with buffer or methyl-β-cyclodextrin (MβCD) to deplete cholesterol and dissolve the structure of lipid rafts. Methods To evaluate lipid raft association, transfected CHO cells were lysed and centrifuged over a sucrose gradient. Fractions were run on SDS-PAGE and blotted for FcγRIIa or sphingolipid GM1 to illustrate the lipid raft fractions. Lateral mobility of GFP-tagged wild-type or mutant FcγRIIa was assessed using fluorescence recovery after photobleaching (FRAP) microscopy. Internalization of IgG-opsonized erythrocytes was assessed by fluorescence microscopy and uptake of heat-aggregated IgG (haIgG) was measured using flow cytometry. Results We observed that FcγRIIa(C208A) did not localize into lipid rafts. However, the mutant FcγRIIa retained lateral mobility and effector function similar to wild-type FcγRIIa. However, mutant FcγRIIa function was abolished upon treatment with MβCD. Conclusions Lipid rafts provide an essential component required for effector activities independent of receptor localization.
- 1 February 2011
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 18 (2) , 210-216
Internalization of IgG-Coated Targets Results in Activation and Secretion of Soluble CD40 Ligand and RANTES by Human Platelets
Platelets are crucial elements for maintenance of hemostasis. Other functions attributable to platelets are now being appreciated, such as their role in inflammatory reactions and host defense. Platelets have been reported to bind immunological stimuli like IgG complexes, and for nearly 50 years it has been speculated that platelets may participate in immunological reactions. Platelets have been reported to bind and internalize various substances, similar to other leukocytes, such as macrophages and dendritic cells. In the present study, we tested the hypothesis that human platelets can bind and internalize IgG-coated particles, similar to leukocytes. To this end, we observed that interaction with IgG-coated beads resulted in platelet activation (as measured by CD62P expression), internalization of targets, and significant soluble CD40 ligand (sCD40L) and RANTES (regulated uponactivation,normalTcellexpresses andsecreted) secretion. Blocking FcγRIIA with monoclonal antibody (MAb) IV.3 or inhibiting actin remodeling with cytochalasin D inhibited platelet activation, internalization, and cytokine production. These data suggest that platelets are capable of mediating internalization of IgG-coated particles, resulting in platelet activation and release of both sCD40L and RANTES.
- 1 February 2011
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 18 (2) , 210-216
Internalization of IgG-Coated Targets Results in Activation and Secretion of Soluble CD40 Ligand and RANTES by Human Platelets
Platelets are crucial elements for maintenance of hemostasis. Other functions attributable to platelets are now being appreciated, such as their role in inflammatory reactions and host defense. Platelets have been reported to bind immunological stimuli like IgG complexes, and for nearly 50 years it has been speculated that platelets may participate in immunological reactions. Platelets have been reported to bind and internalize various substances, similar to other leukocytes, such as macrophages and dendritic cells. In the present study, we tested the hypothesis that human platelets can bind and internalize IgG-coated particles, similar to leukocytes. To this end, we observed that interaction with IgG-coated beads resulted in platelet activation (as measured by CD62P expression), internalization of targets, and significant soluble CD40 ligand (sCD40L) and RANTES (regulated uponactivation,normalTcellexpresses andsecreted) secretion. Blocking FcγRIIA with monoclonal antibody (MAb) IV.3 or inhibiting actin remodeling with cytochalasin D inhibited platelet activation, internalization, and cytokine production. These data suggest that platelets are capable of mediating internalization of IgG-coated particles, resulting in platelet activation and release of both sCD40L and RANTES.
- 31 December 2010
- Published by Elsevier in Cellular Immunology
- Vol. 265 (2) , 111-119
Differential requirement of lipid rafts for FcγRIIA mediated effector activities
- 31 December 2010
- Published by Elsevier in Cellular Immunology
- Vol. 265 (2) , 111-119
Differential requirement of lipid rafts for FcγRIIA mediated effector activities